As the market for anti-obesity medications (AOMs) like GLP-1 receptor agonists (RAs) expands, ADM sees a significant opportunity for food and nutrition brands to serve this growing consumer group with complementary products. Consumers engaging with GLP-1 RA medications have a unique set of needs, and brands that best understand and can best meet these needs have opportunities for new growth.
